603983 Guangdong Marubi Biotechnology
- 32.30
- +0.09+0.28%
Guangdong Marubi Biotechnology News
Marumi Co., Ltd. (603983.SH): Proposed additional investment in the “Smart Cosmetics Manufacturing Plant Construction Project”
Gelonghui, May 20 | Marumei Co., Ltd. (603983.SH) announced that the company plans to invest an additional 68.7526 million yuan in the “Smart Cosmetics Manufacturing Plant Construction Project” to add (expand) construction, add a warehousing and logistics center, support the construction of office and dormitory buildings, and add a new implementation site. The total investment amount of capital raised after the addition is RMB 344.46 million. The total investment amount of capital raised remains unchanged. The company will first complete the construction of civil construction and decoration projects. The shortfall will be covered by self-financing. The scheduled usage date of the “Cosmetics Intelligent Manufacturing Plant Construction Project” has been extended from December 2024
Guangdong Marubi Biotechnology's (SHSE:603983) Profits May Not Reveal Underlying Issues
The market for Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) stock was strong after it released a healthy earnings report last week. However, we think that shareholders should be cautious
Gelonghui Announcements Selected | Mindray Healthcare: Net profit increased 22.9% to 3.16 billion yuan in the first quarter, and all three major international business lines achieved rapid growth; Yunnan Baiyao: Net profit of 1.702 billion yuan in the fir
[Performance data] Sanan Optoelectronics (600703.SH): Net profit of 367 million yuan in 2023, and plans to distribute 0.3 yuan Sanan Optoelectronics (600703.SH) to release the 2023 annual report, achieving operating income of 14.53 billion yuan, an increase of 6.28%; net profit attributable to shareholders of listed companies was 367 million yuan, a year-on-year decrease of 46.50%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - $1,088 million, with basic earnings per share of 0.07 yuan. It is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders. Changsha silver
Marumi Co., Ltd. (603983.SH): Net profit increased by 48.93% to 259 million yuan in 2023, plans to distribute 10 to 5.2 yuan
On April 26, Ge Longhui Co., Ltd. (603983.SH) released its 2023 annual report, achieving operating income of 2,226 billion yuan, an increase of 28.52%; net profit attributable to shareholders of listed companies of 259 million yuan, an increase of 48.93% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 188 million yuan, an increase of 38.16% year on year; and basic earnings per share of 0.65 yuan. It is proposed that all shareholders receive a cash dividend of 5.20 yuan (tax included) for every 10 shares.
Does This Valuation Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Guangdong Marubi Biotechnology fair value estimate is CN¥21.42 Guangdong Marubi Biotechnology's CN¥27.06 share price signals that it might be
Guangdong Marubi Biotechnology (SHSE:603983) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Marumi Co., Ltd. (603983.SH): Obtained a high-tech enterprise certificate
Gelonghui, Feb. 23: Marumei Co., Ltd. (603983.SH) announced that it has received a high-tech enterprise certificate jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. The certificate number is GR202344003218; the date of issue is December 28, 2023; it is valid for three years. After being certified as a high-tech enterprise in 2011, 2014, 2017, and 2020, the company was once again certified as a high-tech enterprise. This is a re-certification carried out after the validity of the company's original high-tech enterprise certificate has expired, and it will not be subject to public approval
Marumi Co., Ltd. (603983.SH): Expected net profit increase of 72% to 89% for 2023
Gelonghui, January 22丨Marumei Co., Ltd. (603983.SH) announced its 2023 annual results forecast. According to preliminary estimates by the company's finance department, it is expected to achieve net profit attributable to owners of the parent company in 2023 of 300,000 yuan to 330 million yuan. Compared with the same period last year, it will increase by 125.82 million yuan to 155.82 million yuan, an increase of 72% to 89% over the previous year. Net profit attributable to owners of the parent company after deducting non-recurring profit and loss is expected to be between RMB 220 million and RMB 250 million in 2023, an increase of 8,4 compared with the same period last year
Marumi Co., Ltd. (603983.SH): The company has carried out a very complete patent layout for SPG
Gelonghui, January 9, 丨 Marumi Co., Ltd. (603983.SH) said in response to a survey of specific subjects that SPG is a fractured polysaccharide based on the bidirectional fermentation system of the medicinal plant Pueraria root and fissure bacteria. It is safe, environmentally friendly, and has excellent hydrating, moisturizing, anti-allergy, and repair effects. SPG-fissured polysaccharide can already be mass-produced on a large scale and will be further promoted and applied in the company's products. The company has carried out a very complete patent layout for SPG.
Marumi Co., Ltd. (603983.SH): The company must use superpower, but it must not form a dependency
Gelonghui, January 9丨Marumi Co., Ltd. (603983.SH) said during an investigation by a specific target that the company needs to use superpower, but it must never become dependent. Strict internal requirements of the company: no department, on any platform, is allowed to break the price for any reason, and to deal with it seriously. We want to be healthy and healthy. We have a basic grasp of how to play on the platform and have begun to innovate gameplay, and are already seeing results. To be a brand, you must not only look at the present; you must have your own inner persistence. Price control is a job that the company has always attached great importance to, and it will also be a very important job for the company in 2024.
Marumi Co., Ltd. (603983.SH): Insist on dividing products, online and offline, focusing on offline series
Gelonghui, January 9 | Marumei Co., Ltd. (603983.SH) said in response to a specific survey, that it insists on dividing products, online and offline products, with offline main series, crystal series, recombinant collagen series, polypeptide series, elastin series, etc., with a unit price of 300-500 customers, mainly for people aged 35 and above, mainly for cities below the 3rd and 4th tier; online is mainly promoting a large single product strategy, with eye cream and massager 2-in-1, recombinant double collagen, small gold needle essence, and the single price for customers aged 25-35 Mainly, reverse osmosis to Tier 1 and 2 cities is clearly visible. The company carried out the channel by adjusting the product structure
Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Guangdong Marubi Biotechnology (SHSE:603983) has had a great run on the share market with its stock up by a significant 16% over the last week. But the company's key financial indicators appear to b
Guotai Junan: Leading domestic cosmetics brands have entered a stage of rapid increase in market share
Guotai Junan released a research report saying that it continues to be optimistic that leading domestic cosmetics brands will continue to promote product innovation on the basis of more efficient market feedback and channel operations, and enter a stage where market share is rapidly increasing.
Guangdong Marubi Biotechnology (SHSE:603983) May Have Issues Allocating Its Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE)
Guotai Junan: Under the overall sluggishness of Double Eleven, the rise of domestic cosmetics is optimistic that leading domestic products will continue to seize share
The turnover of the entire Double Eleven network was +2% compared to the same period last year. Overall, beauty was lackluster, and Douyin maintained rapid growth.
Marumi Co., Ltd. (603983.SH): Recombinant collagen has been widely used in Marumi products
Glonghui November 8 | Marumi Co., Ltd. (603983.SH) stated on an interactive platform that recombinant collagen has been widely used in Marumi products, such as essences, cleansers, toners, lotions, eye creams, face creams, facial masks, etc. Among them, the core component of Marumi Kogane Throw Essence is recombinant collagen. According to third-party test report data, the product had the effect of improving wrinkles after 10 days of testing, and there were no adverse effects on sensitive skin after 28 days of testing the product. Marumi's recombinant collagen series products are facial care products. They can be used on facial wrinkles, sagging skin, prone to allergies, and unstable skin
Marumi Co., Ltd. (603983.SH): There is no cooperation with Huawei
On November 8, GLONGHUI Co., Ltd. (603983.SH) stated on an interactive platform that the company's main business is cosmetics R&D, production, sales and service, and there is no cooperation with Huawei.
Marumi Co., Ltd. (603983.SH): Net profit for the first three quarters was 174 million yuan, up 44.84% year on year
On October 30, Marumi Co., Ltd. (603983.SH) released its report for the first three quarters of 2023. During the reporting period, it achieved operating income of 1,536 billion yuan, up 34.34% year on year; net profit attributable to shareholders of listed companies was 174 million yuan, up 44.84% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 157 million yuan, up 75.99% year on year; basic earnings per share of 0.43 yuan.
Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Shares Could Be 23% Above Their Intrinsic Value Estimate
Key Insights The projected fair value for Guangdong Marubi Biotechnology is CN¥19.27 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥23.75 suggests Guangdong Marubi Biotechnology
Is Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Stock Price Struggling As A Result Of Its Mixed Financials?
Guangdong Marubi Biotechnology (SHSE:603983) has had a rough three months with its share price down 24%. We, however decided to study the company's financials to determine if they have got anything
Analysis
Price Target
No Data
